The selective prostacyclin (IP) receptor agonist selexipag: first sparse experience in pediatric pulmonary arterial hypertension

被引：0
|
作者：
Koestenberger, M.
Gamillscheg, A.
Avian, A.
Grangl, G.
Burmas, A.
Schweintzger, S.
Baumgartner, D.
Cvirn, G.
Kurath-Koller, S.
Hansmann, G.
机构：
[1] Med Univ Graz, Dept Pediat, Div Pediat Cardiol, Graz, Austria
[2] Med Univ Graz, Inst Med Informat Stat & Documentat, Granz, Austria
[3] Med Univ Graz, Inst Physiol Chem, Ctr Physiol Med, Graz, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2018年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
10-3
引用
收藏
页码：76 / 77
页数：2
相关论文
共 50 条
  • [1] Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
    Asaki, Tetsuo
    Kuwano, Keiichi
    Morrison, Keith
    Gatfield, John
    Hamamoto, Taisuke
    Clozel, Martine
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (18) : 7128 - 7137
  • [2] Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension
    Martin Koestenberger
    Georg Hansmann
    [J]. Pediatric Cardiology, 2017, 38 : 1523 - 1524
  • [3] Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension
    Koestenberger, Martin
    Hansmann, Georg
    [J]. PEDIATRIC CARDIOLOGY, 2017, 38 (07) : 1523 - 1524
  • [4] First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
    Geerdink, Lianne M.
    Bertram, Harald
    Hansmann, Georg
    [J]. PULMONARY CIRCULATION, 2017, 7 (02) : 551 - 554
  • [5] Pulmonary arterial hypertension: selexipag Selective prostacyclin receptor agonist orally
    Lobo Marquez, Lilia Luz
    Bevacqua, Raul J.
    [J]. INSUFICIENCIA CARDIACA, 2019, 14 (01) : 34 - 44
  • [6] Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review
    Honorato Perez, Jesus
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (07) : 753 - 762
  • [7] Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
    Simonneau, Gerald
    Torbicki, Adam
    Hoeper, Marius M.
    Delcroix, Marion
    Karlocai, Kristof
    Galie, Nazzareno
    Degano, Bruno
    Bonderman, Diana
    Kurzyna, Marcin
    Efficace, Michela
    Giorgino, Ruben
    Lang, Irene M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (04) : 874 - 880
  • [8] Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension
    Baker, William L.
    Darsaklis, Konstadina
    Singhvi, Aditi
    Salerno, Edward L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2017, 51 (06) : 488 - 495
  • [9] Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension
    Tanabe, Nobuhiro
    Ikeda, Satoshi
    Tahara, Nobuhiro
    Fukuda, Keiichi
    Hatano, Masaru
    Ito, Hiroshi
    Nakayama, Tomotaka
    Anzai, Toshihisa
    Hashimoto, Akiyoshi
    Inoue, Teruo
    Kajinami, Kouji
    Kihara, Yasuki
    Kinoshita, Hideyuki
    Kuwahara, Koichiro
    Murohara, Toyoaki
    Okazaki, Osamu
    Sakai, Satoshi
    Satoh, Toru
    Takeda, Yutaka
    Takeishi, Yasuchika
    Taniguchi, Mitsugu
    Watanabe, Hiroshi
    Yamamoto, Takeshi
    Yamauchi-Takihara, Keiko
    Yoshioka, Koichiro
    Sasayama, Shigetake
    [J]. CIRCULATION JOURNAL, 2017, 81 (09) : 1360 - 1367
  • [10] Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome
    Demerouti, Eftychia A.
    Karyofyllis, Panagiotis
    Apostolopoulou, Sotiria C.
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2021, 37 (08) : 1286 - 1288
12345